Neurofibromatoses Type II – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Neurofibromatoses Type II – Pipeline Review, H2 2016’, provides an overview of the Neurofibromatoses Type II pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Neurofibromatoses Type II, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Neurofibromatoses Type II and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Neurofibromatoses Type II

The report reviews pipeline therapeutics for Neurofibromatoses Type II by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Neurofibromatoses Type II therapeutics and enlists all their major and minor projects

The report assesses Neurofibromatoses Type II therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Neurofibromatoses Type II

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Neurofibromatoses Type II

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Neurofibromatoses Type II pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Arno Therapeutics, Inc.

Betta Pharmaceuticals Co. Ltd.

Lixte Biotechnology Holdings, Inc.

Novartis AG

Plex Pharmaceuticals, Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

Neurofibromatoses Type II Overview 6

Therapeutics Development 7

Pipeline Products for Neurofibromatoses Type II - Overview 7

Pipeline Products for Neurofibromatoses Type II - Comparative Analysis 8

Neurofibromatoses Type II - Therapeutics under Development by Companies 9

Neurofibromatoses Type II - Therapeutics under Investigation by Universities/Institutes 10

Neurofibromatoses Type II - Pipeline Products Glance 11

Clinical Stage Products 11

Early Stage Products 12

Neurofibromatoses Type II - Products under Development by Companies 13

Neurofibromatoses Type II - Products under Investigation by Universities/Institutes 14

Neurofibromatoses Type II - Companies Involved in Therapeutics Development 15

Arno Therapeutics, Inc. 15

Betta Pharmaceuticals Co. Ltd. 16

Lixte Biotechnology Holdings, Inc. 17

Novartis AG 18

Plex Pharmaceuticals, Inc. 19

Neurofibromatoses Type II - Therapeutics Assessment 20

Assessment by Monotherapy Products 20

Assessment by Target 21

Assessment by Mechanism of Action 23

Assessment by Route of Administration 25

Assessment by Molecule Type 27

Drug Profiles 29

AR-42 - Drug Profile 29

Product Description 29

Mechanism Of Action 29

R&D Progress 29

everolimus - Drug Profile 31

Product Description 31

Mechanism Of Action 31

R&D Progress 31

FRAX-597 - Drug Profile 43

Product Description 43

Mechanism Of Action 43

R&D Progress 43

icotinib hydrochloride - Drug Profile 44

Product Description 44

Mechanism Of Action 44

R&D Progress 44

LB-201 - Drug Profile 46

Product Description 46

Mechanism Of Action 46

R&D Progress 46

LB-205 - Drug Profile 47

Product Description 47

Mechanism Of Action 47

R&D Progress 47

Small Molecule to Inhibit Hsp90-Alpha and TRAP1 for Neurofibromatosis Type 2 - Drug Profile 48

Product Description 48

Mechanism Of Action 48

R&D Progress 48

Vaccine to Target VEGFR1 and VEGFR2 for Oncology - Drug Profile 49

Product Description 49

Mechanism Of Action 49

R&D Progress 49

Neurofibromatoses Type II - Dormant Projects 50

Neurofibromatoses Type II - Product Development Milestones 51

Featured News & Press Releases 51

May 11, 2012: Arno Therapeutics Receives European Orphan Drug Designation For AR-42 51

Appendix 52

Methodology 52

Coverage 52

Secondary Research 52

Primary Research 52

Expert Panel Validation 52

Contact Us 52

Disclaimer 53

List of Tables

List of Tables

Number of Products under Development for Neurofibromatoses Type II, H2 2016 7

Number of Products under Development for Neurofibromatoses Type II – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Development, H2 2016 12

Products under Development by Companies, H2 2016 13

Products under Investigation by Universities/Institutes, H2 2016 14

Neurofibromatoses Type II – Pipeline by Arno Therapeutics, Inc., H2 2016 15

Neurofibromatoses Type II – Pipeline by Betta Pharmaceuticals Co. Ltd., H2 2016 16

Neurofibromatoses Type II – Pipeline by Lixte Biotechnology Holdings, Inc., H2 2016 17

Neurofibromatoses Type II – Pipeline by Novartis AG, H2 2016 18

Neurofibromatoses Type II – Pipeline by Plex Pharmaceuticals, Inc., H2 2016 19

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Stage and Target, H2 2016 22

Number of Products by Stage and Mechanism of Action, H2 2016 24

Number of Products by Stage and Route of Administration, H2 2016 26

Number of Products by Stage and Molecule Type, H2 2016 28

Neurofibromatoses Type II – Dormant Projects, H2 2016 50

List of Figures

List of Figures

Number of Products under Development for Neurofibromatoses Type II, H2 2016 7

Number of Products under Development for Neurofibromatoses Type II – Comparative Analysis, H2 2016 8

Number of Products under Development by Companies, H2 2016 9

Number of Products under Investigation by Universities/Institutes, H2 2016 10

Comparative Analysis by Clinical Stage Development, H2 2016 11

Comparative Analysis by Early Stage Products, H2 2016 12

Assessment by Monotherapy Products, H2 2016 20

Number of Products by Targets, H2 2016 21

Number of Products by Stage and Top 10 Targets, H2 2016 21

Number of Products by Mechanism of Actions, H2 2016 23

Number of Products by Stage and Mechanism of Actions, H2 2016 23

Number of Products by Routes of Administration, H2 2016 25

Number of Products by Stage and Routes of Administration, H2 2016 25

Number of Products by Molecule Types, H2 2016 27

Number of Products by Stage and Molecule Types, H2 2016 27

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports